Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.

Maison has spent most of his life being treated in hospital and currently can not play with other children due to his ...

Toddler with rare blood disorder needs stem cell match to survive - Maison was diagnosed with Wiskott-Aldrich syndrome (WAS) ...

BioMarin Pharmaceutical said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding disorder.

With a $157 million series C funding round, Hemab Therapeutics is looking to infuse innovation into the treatment landscape ...

Extended half-life therapies Eloctate and Alprolix safely and effectively controlled bleeds in hemophilia patients' surgeries ...